APA (7th ed.) Citation

Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, & Felicetto Ferrara. (2023). Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC.

Chicago Style (17th ed.) Citation

Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, and Felicetto Ferrara. Cost-effectiveness Analysis of Gemtuzumab Ozogamicin for the Treatment of De Novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC, 2023.

MLA (9th ed.) Citation

Roberto Cairoli, et al. Cost-effectiveness Analysis of Gemtuzumab Ozogamicin for the Treatment of De Novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC, 2023.